Evidence map›Paper›PMID 25406193›Full record

ArticleCancer research2015

Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone.

Sara Gm Piccirillo, Inmaculada Spiteri, Andrea Sottoriva, Anestis Touloumis, Suzan Ber, Stephen J Price, Richard Heywood, Nicola-Jane Francis, Karen D Howarth, Vincent P Collins and 5 more

Registry-linked trialAbstract read
In one paragraph

Article in Cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03956706 (Phase I Study of Subventricular Zone Tumor Stem Cell Stereotactic Radiosurgery With Standard of Care Chemoradiation Therapy in Newly Diagnosed Malignant Gliomas), which is not on this map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03956706 nawithdrawnnot on this mapstarted 2018, after this paper: background citation

Phase I Study of Subventricular Zone Tumor Stem Cell Stereotactic Radiosurgery With Standard of Care Chemoradiation Therapy in Newly Diagnosed Malignant Gliomas (WHO III and WHO IV Astrocytomas)

TypeinterventionalSponsorNorthwell HealthRan2018 to 2022Enrolled0ConditionsGlioblastoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Malignant GliomaArmsStereotactic Radiosurgery
3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. The inverse paradigm and the ancestral cell of IDH-wildtype glioblastoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Article
  12. Article
  13. Article
  14. Influence of glioblastoma contact with the subventricular zone on survival and recurrence patterns.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  15. Advances in Research of Adult Gliomas.International journal of molecular sciences · 2021
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sara Gm PiccirilloJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Inmaculada Spiteri *Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK.
Andrea Sottoriva *Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK.
Anestis TouloumisCancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK.
Suzan BerJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Stephen J PriceDivision of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Richard HeywoodJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Nicola-Jane FrancisDepartment of Oncology and the Medical Research Council Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge, UK.
Karen D HowarthHutchison/MRC Research Centre and Department of Pathology, University of Cambridge, Cambridge, UK.
Vincent P CollinsDivision of Molecular Histopathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Ashok R VenkitaramanDepartment of Oncology and the Medical Research Council Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge, UK.
Christina CurtisDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
John C MarioniEuropean Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
Simon TavaréCancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK.
Colin WattsJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

Funding

Cancer Research UK 14545Cancer Research UK 16700Cancer Research UK A10825Cancer Research UK A14545Cancer Research UK C1023/A14545Cancer Research UK C14303/A10825Department of Health NIHR/CS/009/011Medical Research Council G1001522Medical Research Council MC_UU_12022/1Wellcome Trust 090340
6 · The paper itself

Abstract

Glioblastoma, the most common and aggressive adult brain tumor, is characterized by extreme phenotypic diversity and treatment failure. Through fluorescence-guided resection, we identified fluorescent tissue in the sub-ependymal zone (SEZ) of patients with glioblastoma. Histologic analysis and genomic characterization revealed that the SEZ harbors malignant cells with tumor-initiating capacity, analogous to cells isolated from the fluorescent tumor mass (T). We observed resistance to supramaximal chemotherapy doses along with differential patterns of drug response between T and SEZ in the same tumor. Our results reveal novel insights into glioblastoma growth dynamics, with implications for understanding and limiting treatment resistance.

Indexed as

Brain NeoplasmsCell Line, TumorDrug Resistance, NeoplasmEpendymaGlioblastomaHumansNeoplastic Stem CellsNeural Stem Cells

Identifiers

PMID25406193
PMCPMC4286248

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.